Back to results
US 2026/0086103 A1Published application
Biomarkers for cardiovascular events
AssigneeZora Biosciences Oy
InventorsMika HILVO, Reijo LAAKSONEN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods and uses involving the determination of lipid concentrations in order to diagnose, predict, prevent and/or treat one or more cardiovascular events in a subject. The methods include analyzing lipid concentrations of a sample from the subject and comparing them to a control.
Claims20
A method for determining the risk of a subject to develop one or more cardiovascular (CV) events, wherein the method comprises
- (a) assaying a sample from the subject to determine a concentration of at least one ceramide (Cer) of Formula I:
- wherein R1 is a saturated, mono-unsaturated or di-unsaturated alkyl chain having 11-17 carbon atoms, and wherein R2 is a saturated, mono-unsaturated or di-unsaturated alkyl chain having 13-25 carbon atoms, wherein the at least one Cer of Formula I comprises Cer(d18:1/16:0);
- (b) assaying the sample from the subject to determine a concentration of at least one phosphatidylcholine (PC) of Formula II:
- wherein R3 and R4 are saturated, mono-unsaturated or polyunsaturated alkyl chains, wherein the at least one PC of Formula II comprises PC 16:0/22:5;
- and
- (c) determining that the subject has a risk to develop one or more CV events, if the sample contains (an) increased concentration(s) of the at least one Cer of Formula I and/or (a) decreased concentration(s) of the at least one PC of Formula II, when compared to a control.
3 more elements
A method for determining the risk of a subject to develop one or more cardiovascular (CV) events, wherein the method comprises
- (a) assaying a sample from the subject to determine a concentration of Cer(d18:1/16:0) and a concentration of PC 16:0/22:5, wherein the assaying comprises using d7-Cer(d18:1/16:0) and d9-PC 16:0/22:5;
- (b) determining a concentration ratio from the concentrations of Cer(d18:1/16:0) and PC 16:0/22:5, wherein the concentration ratio comprises Cer(d18:1/16:0)/PC 16:0/22:5;
- and
- (c) determining that the subject has a risk to develop one or more CV events, if the sample contains an increased Cer(d18:1/16:0)/PC 16:0/22:5 concentration ratio, when compared to a control.
1 more element
Dependencies are inferred from the claim text.